AGPAT5 Antibody - #DF3641

(1)   (5)  
Product: AGPAT5 Antibody
Catalog: DF3641
Description: Rabbit polyclonal antibody to AGPAT5
Application: WB IHC IF/ICC
Reactivity: Human, Mouse
Prediction: Horse, Dog
Mol.Wt.: 45 KD; 42kD(Calculated).
Uniprot: Q9NUQ2
RRID: AB_2836013

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:1000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse
Prediction:
Horse(86%), Dog(86%)
Clonality:
Polyclonal
Specificity:
AGPAT5 Antibody detects endogenous levels of total AGPAT5.
RRID:
AB_2836013
Cite Format: Affinity Biosciences Cat# DF3641, RRID:AB_2836013.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

1 acyl sn glycerol 3 phosphate acyltransferase epsilon; 1 acylglycerol 3 phosphate O acyltransferase 5; 1 AGP acyltransferase 5; 1 AGPAT 5; 1 AGPAT5; 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon; 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon); 1-acylglycerol-3-phosphate O-acyltransferase 5; 1-AGP acyltransferase 5; 1-AGPAT 5; 1acylglycerol3phosphate Oacyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon); 1acylglycerol3phosphate Oacyltransferase 5; 1acylglycerol3phosphate Oacyltransferase5 (lysophosphatidic acid acyltransferase, epsilon); 1AGP acyltransferase 5; 1AGPAT5; AGPAT5; LPAAT e; LPAAT epsilon; LPAAT-epsilon; LPAATE; Lysophosphatidic acid acyltransferase epsilon; PLCE_HUMAN;

Immunogens

Immunogen:
Uniprot:

Q9NUQ2(PLCE_HUMAN) >>Visit HPA database.

Gene(ID):
AGPAT5(55326)
Expression:
Q9NUQ2 PLCE_HUMAN:

Widely expressed.

Sequence:
MLLSLVLHTYSMRYLLPSVVLLGTAPTYVLAWGVWRLLSAFLPARFYQALDDRLYCVYQSMVLFFFENYTGVQILLYGDLPKNKENIIYLANHQSTVDWIVADILAIRQNALGHVRYVLKEGLKWLPLYGCYFAQHGGIYVKRSAKFNEKEMRNKLQSYVDAGTPMYLVIFPEGTRYNPEQTKVLSASQAFAAQRGLAVLKHVLTPRIKATHVAFDCMKNYLDAIYDVTVVYEGKDDGGQRRESPTMTEFLCKECPKIHIHIDRIDKKDVPEEQEHMRRWLHERFEIKDKMLIEFYESPDPERRKRFPGKSVNSKLSIKKTLPSMLILSGLTAGMLMTDAGRKLYVNTWIYGTLLGCLWVTIKA

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
86
Dog
86
Rabbit
79
Pig
71
Bovine
64
Sheep
64
Chicken
64
Zebrafish
43
Xenopus
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q9NUQ2 As Substrate

Site PTM Type Enzyme
S39 Phosphorylation
K120 Ubiquitination
K150 Ubiquitination
K155 Ubiquitination
T164 Phosphorylation
K183 Ubiquitination
K201 Acetylation
K201 Ubiquitination
K209 Ubiquitination
Y221 Phosphorylation
Y232 Phosphorylation
K253 Ubiquitination
K257 Ubiquitination
K310 Ubiquitination
K315 Ubiquitination
T321 Phosphorylation
S324 Phosphorylation
T338 Phosphorylation

Research Backgrounds

Function:

Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. Acts on LPA containing saturated or unsaturated fatty acids C15:0-C20:4 at the sn-1 position using C18:1-CoA as the acyl donor. Also acts on lysophosphatidylethanolamine using oleoyl-CoA, but not arachidonoyl-CoA, and lysophosphatidylinositol using arachidonoyl-CoA, but not oleoyl-CoA. Activity toward lysophosphatidylglycerol not detectable.

Subcellular Location:

Endoplasmic reticulum membrane>Multi-pass membrane protein. Nucleus envelope. Mitochondrion.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Widely expressed.

Family&Domains:

The HXXXXD motif is essential for acyltransferase activity and may constitute the binding site for the phosphate moiety of the glycerol-3-phosphate.

Belongs to the 1-acyl-sn-glycerol-3-phosphate acyltransferase family.

Research Fields

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Metabolism > Lipid metabolism > Glycerolipid metabolism.

· Metabolism > Lipid metabolism > Glycerophospholipid metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

References

1). The prognostic value of the GPAT/AGPAT gene family in hepatocellular carcinoma and its role in the tumor immune microenvironment. Frontiers in Immunology, 2023 (PubMed: 36845084) [IF=7.3]

Application: IHC    Species: Human    Sample: tumor tissues

Figure 8 Preliminary validation of AGPAT5, LCLAT1, and LPCAT1. (A) Immunohistochemistry of HCC tumor tissues and adjacent normal tissues. (B–D) CCK-8 assay (B), migration assay (C), and invasion assay (D) after knockdown of AGPAT5, LCLAT1, and LPCAT1 in HepG2 using siRNA and non-targeted control siRNA, respectively. (E) Western blotting validation of knockdown efficacy after transfection of HepG2 using siRNA and non-targeting control siRNA. (F) Validation of common tumor-associated protein markers after knockdown of AGPAT5. (G) Validation of common tumor-associated protein markers after knockdown of LCLAT1. (H) Validation of common tumor-associated protein markers after knockdown of LPCAT1. Representative images are shown. Magnification 100x; scale bar: 200 μm. Significance signs:

Application: WB    Species: Human    Sample: tumor tissues

Figure 8 Preliminary validation of AGPAT5, LCLAT1, and LPCAT1. (A) Immunohistochemistry of HCC tumor tissues and adjacent normal tissues. (B–D) CCK-8 assay (B), migration assay (C), and invasion assay (D) after knockdown of AGPAT5, LCLAT1, and LPCAT1 in HepG2 using siRNA and non-targeted control siRNA, respectively. (E) Western blotting validation of knockdown efficacy after transfection of HepG2 using siRNA and non-targeting control siRNA. (F) Validation of common tumor-associated protein markers after knockdown of AGPAT5. (G) Validation of common tumor-associated protein markers after knockdown of LCLAT1. (H) Validation of common tumor-associated protein markers after knockdown of LPCAT1. Representative images are shown. Magnification 100x; scale bar: 200 μm. Significance signs:

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.